SMi Pharmacovigilance

Venue: Copthorne Tara Hotel

Location: London, United Kingdom

Event Date/Time: Mar 14, 2011 End Date/Time: Mar 15, 2011
Report as Spam


SMi Group is proud to announce the much anticipated follow up to its inaugural Pharmacovigilance Summit, taking place in London on the 14th and 15th March, 2011. Offering an intensive two day program and designed to keep you up to date with the latest developments in the industry and meet fellow key decision makers; this promises to be another great event in SMi’s outstanding portfolio of clinical pharmaceutical conferences.

Featuring 18 leading industry expert speakers, the jam packed CPD Accredited program addresses key such areas as:

Practical challenges in PhV inspections
Updates on the DSUR
New risk management activities
Signal detection and managing PhV data

All designed to provide the most complete and content driven Pharmacovigilance Summit around.

Our key Industry Leading Speakers Include

Peter Schiemann, Global Head of Quality Risk Management, Hoffmann-La Roche

Stewart Geary, Vice President, Deputy Director,
Corporate Regulatory Compliance and Quality Assurance Headquarters, Eisai

Mariska Kooijmans-Coutinho, Vice President Drug Safety and Risk Management, and QPPV, Biogen Idec

George McCormick, Vice President, Drug Safety & Disposition, Cephalon

Shelley Gandhi, Unit Manager-Signal Management GroupVigilance & Risk Management of Medicines, MHRA

Michèle Sangeleer, Medical Information & Pharmacovigilance Manager, Eli Lilly

Barbara Donner, Global Head of Safety Science Business Support, Hoffmann-La Roche

Heide Cunning, Director, Safety Operations, Ortho-Mcneil Janssen (A Johnson and Johnson Company)

Karen Pattenden, Senior Director Drug Safety & Public Health/EEA QPPV, Gilead Sciences International ltd

Patricia Bocciarelli, International Pharmacovigilance Expert Clinical Quality & Compliance, Sanofi-Aventis


Additional Information

PLUS THE NOT TO BE MISSED INTERACTIVE WORKSHOP ENTITLED: Optimising Pharmacovigilance in Affiliates Hosted By: Katja Kusche, Global Head of Safety Science for Mature Product of Hoffmann-La Roche